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Variable (N)
Median time to
progression (p-value)
Median
overall survival
(p-value)
Treatment related
mortality at 2 years (p-value)
HCT year <2000 (47) 1.6 years (0.41) 4.9 months (0.04) 55% (0.001)
HCT year $ 2000 (102) 10 months 1.4 years 28%
Male (87) 10 months (0.34) 1.1 years (0.8)
Female (62) 1.2 years 8.8 months
Age > 50 years (65) 10 months (0.93) 1.6 years (0.14) 25% (0.08)
Age # 50 years (84) 1.1 years 7.6 months 47%
Durie Salmon Stage I/II (78) 1.1 years (0.81) 1.9 years (0.08)
Durie Salmon Stage III (71) 10 months 8.5 months
Myeloablative conditioning (52) 10 months (0.45) 5.3 months (0.08) 52% (0.009)
Reduced intensity conditioning (97) 10 months 1.3 years 29%
Related donor (114) 10 months (0.35) 1.4 years (0.27)
Unrelated donor (35) 10 months 8.5 months
Stem cell source peripheral blood (100) 1.2 years (0.11) 1.7 years (<0.001) 29% (0.002)
Stem cell source cord blood (3) 5.6 months 13 days
Stem cell source bone marrow (46) 7.5 months 5 months 54%
Disease status at HCT PR or better (76) 1.4 years (0.03) 1.7 years (0.001) 30% (0.016)
Disease status at transplant less than PR (72) 9 months 5.3 months 45%
Maintenance therapy given (12) 10 months (0.7) 2.9 years (0.06)
No maintenance therapy (137) 1 year 8.4 months
Relapsed/refractory disease (121) 9 months (<0.001) 7.8 months (<0.0001)
Primary responsive disease (26) Not reached 6.48 years
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AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE
MYELOMA PATIENTS AGE 70 YEARS AND OLDER
Bashir, Q.1, Wei, W.1, Chiattone, A.1, Rondon, G.1, Parmar, S.1,
Shah, N.1, Booc, E.H.1, Dinh, Y.1, Qureshi, S.1, Shah, J.1,
Orlowski, R.Z.1, Weber, D.1, Champlin, R.E.1, Giralt, S.2,
Qazilbash, M.H.1 1University of Texas M.D. Anderson Cancer Center,
Houston, TX; 2Memorial Sloan Kettering Cancer Center, New York, NY
Introduction:High dose chemotherapy followed by autologous he-
matopoietic cell transplantation (auto HCT) for multiple myeloma
(MM) has shown improved survival compared to conventional che-
motherapy. However, the larger clinical trials evaluating the role
of auto HCT inMM have included patients who are generally youn-
ger than 65 years. Here we report the results of MM patients, age$
70 years, who received auto HCT at our institution.
Methods:We retrospectively analyzed 84 patients, who underwent
auto HCT between January 1999 and June 2010 at MDACC. Con-
ditioning regimen was Melphalan 140 mg/m2 (MEL 140) (N 5 9),
180 mg/m2 (MEL 180) (N 5 20), and 200 mg/m2 (MEL 200) (N
5 55). Disease response was assessed at day 100 post transplant.
Results: Pertinent patient and disease characteristics are summa-
rized in the Table.
Progression-Variable (N)Progression-free
survival
at 2 yearsfree
survival
at 5 years aOverall
survival
t 2 years
sOverall
urvival at
5 years
Non-relapse
mortality
(day100)All patients (84) 56% 28% 80% 66% 2%MEL-140 (9) 75% NA 75% NA 0MEL-180 (20) 62% 44% 94% 60% 0MEL-200 (55) 50% 21% 75% 72% 4%Relapse/Refractory
disease (24)41% NA* 64% 41%** 0Primary responsive
disease (60)63% 43% 89% 82% 3%Age $ 75 years (18) 73% 40% 83 83 6Age < 75 years (66) 52% 26% 79% 63% 2%*p value 5 0.008
**p value 5 0.005
Median age at transplant was 72 (70-80) years. Median number of
prior treatments was 1 (range: 1-8). Median time from diagnosis to
transplant was 8.5 (2.4-151) months. No patient was in CR prior
to auto HCT. Median CD341 cell count and TNC was 4.56
(0.72-11.1)  106/kg and 10.53 (2.25-57) x108/kg, respectively.
Median follow up is 2 (0.1-7.3) years. Grade III-IV organ toxicity
was seen in 35 (51%) patients. Grade III-IV toxicity in patientswho received MEL 140, MEL 180, and MEL 200 was 25%, 45%,
and 44%, respectively (p value . 0.05). Non-relapse mortality
(NRM) at 100 days was 2%. Two patients died in first 100 days. Dis-
ease response in evaluable patients (N5 79) at day 100 was: CR5 15
(19%); VGPR5 7 (9%); PR5 41 (52%); and SD 5 10 (13%). Me-
dian progression free survival (PFS) and overall survival (OS) from
auto HCT was 2.1 years (95% CI 1.78-3.69) and 5.6 years (95%
CI 5.51-NA), respectively. 2-year PFS and OS were 56% (95% CI
0.44-0.71) and 80% (95% CI 0.7-0.91), respectively. There was no
difference in NRM, PFS, or OS in different MEL groups. Similarly
there was no difference in TRM, PFS, and OS in patients$ 75 years
compared to the patients\ 75 years.
Conclusions: Auto HCT in myeloma patients age$ 70 years is safe
and feasible. Toxicity, NRM, response and survival were comparable
to younger myeloma patients. The age alone should not be a contra-
indication for auto HCT.69
INHIBITING IMMUNE SUPPRESSIVE PATHWAYS TO IMPROVE IMMUNO-
THERAPY FOR MYELOMA
Hallett, W.H.D., Drobyski, W.R., Johnson, B.D. Medical College of
Wisconsin, Milwaukee, WI
Myeloma is an incurable hematologic malignancy. Patients who
fail conventional treatments may be treated with high-dose therapy
followed by hematopoietic stem cell transplantation (HSCT). Un-
fortunately, these patients frequently relapse from sites of treat-
ment-resistant disease. Upon examining marrow and blood
samples frommyeloma patients, our laboratory confirmed recent ob-
servations by others showing high expression of B7-H1 on plasma
cells and high levels of the inhibitory receptor PD-1 (receptor for
B7-H1) on T cells in these patients.When tissues frommice bearing
myeloma (5T33 myeloma) were examined, we observed a similar
pattern of B7-H1 and PD-1 expression. Increased expression of
PD-1 on T cells (both CD4 and CD8) and NK cells in myeloma-
bearing mice correlated with tumor burden and was restricted to
areas of local tumor cell accumulation. CD81PD-11 T cells were
CD44hi/CD62L-, a large percentage bound annexin-V, and they
produced interferon-gamma, suggesting that these cells are termi-
nally differentiated effectors.
A combined immunotherapy approach that incorporates HSCT,
adoptive transfer of T lymphocytes, and administration of a cell-
based vaccine was unable to eliminate established 5T33 myeloma.
We hypothesized that failure of this immunotherapy to be effective
was due to immune suppression mediated by the B7-H1/PD-1 path-
way. To address this hypothesis, we administered a B7-H1 blocking
antibody to myeloma-bearing mice during the vaccine phase
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significantly improved long-term survival after immunotherapy
(40% vs 0% for controls), indicating that the B7-H1/PD-1
pathway inhibits development of myeloma-specific immunity. We
are addressing that possibility that other immune suppressive
mechanisms can be targeted to further improve immunotherapy
efficacy, and several candidates have been identified including
CD41Foxp31 regulatory T cells. These results support the use of
B7-H1/PD-1 blocking strategies to increase tumor immunity in
myeloma patients.70
BINARY CONTROL OF TUMOR-SPECIFIC CYTOTOXIC T LYMPHOCYTES BY
TRANSGENIC IL7 AND IL7 RECEPTOR EXPRESSION
Vera, J.F., Sanchez, C.L.,Muralidharan, S., Heslop, H.E., Rooney, C.M.,
Dotti, G., Brenner, M.K. Center for Cell and Gene Therapy CAGT,
Houston, TX
While adoptive transfer of cytotoxic T lymphocytes (CTLs) en-
grafted with chimeric antigen receptors (CARs) has produced objec-
tive clinical responses in vivo, the infused cells usually fail to persist
long-term, limiting benefit. We have recently demonstrated that
CTL persistence can be improved by engineering cells to express
the IL7 receptor alpha chain (IL7Ra) which is physiologically absent
on CTLs, followed by infusion of IL7 cytokine. However, this ap-
proach requires access to clinical grade cytokine, and biodistribution
of cytokine at tumor sites may be insufficient. To circumvent these
problems we have prepared two CTL products; one expressing a tu-
mor-specific CAR in combination with IL7Ra (product #1), and
a second engineered to co-express the same CAR and produce IL7
cytokine (product #2). In this way both products have anti-tumor ac-
tivity, mediated through the CAR, while cytokine produced from
CTL#2 should support the survival and persistence of CTL#1 ex-
pressing the IL7Ra. A binary system such as this should be intrinsi-
cally safer than incorporating a positive feedback loop of both
cytokine and receptor in a single cell.
As proof of principal we used the SFG-CAR that targets the kappa
light chain, expressed on B cell malignancies. We made two retrovi-
ral vectors, SFG-CAR/IL7Ra-GFP (#1) and SFG-CAR/IL7cyto-
mOrange (#2) and transduced EBV-CTL from 3 donors with each
vector. FACS analysis indicated that all the transgenes were ex-
pressed at approx. equivalent levels; CTL#1 (CAR, IL7Ra andPatient
Days Required
for Collection
Days to
Collection
CD34+ Stem Cells
(million/kg) in
1 1 18 21.2
2 1 18 47.4
3 1 19 22
4 1 18 17.9
5 4 19 40.6
6 1 18 19.9
7 3 19 294.2
8 2 17 13.8
9 5 18 9.25
10 2 17 21.4
11 1 24 50.0
12 2 19 66.12
13 1 18 30.4
14 2 16 43.6
15 1 19 51.0
16 1 17 15.56
17 1 17 6.8
18 1 17 31.67
19 1 17 7.8
20 1 16 43.9
21 1 18 23.2
22 1 17 14.0
23 2 17 2.946
24 1 16 32.8
25 1 20 11.5
median 1 18 22GFP; 58%615, 53%618, 57.8%612) and CTL#2 (CAR and mOr-
ange; 54%618 and 52%620). The modified CTL were functional,
and cells transduced with either vector were able to kill the Kappa1
B cell tumor Daudi in Cr51 assay (72%613 and 69%625, respec-
tively) at an R:S of 40:1. We confrmed the function of IL7Ra (#1)
by measuring pSTAT5 and cell proliferation after IL7 administra-
tion (67,64862703 CPM vs 8,7646793 CPM when cells were cul-
tured in media). In addition, we were able to measure IL7 cytokine
from product #2 by ELISA. IL7 production was dependent on the
intensity of antigenic stimulation as demonstrated using different ra-
tios of CTL:EBV-LCLs (4:1, 2:1, 1:1 and 1:2 which induced 3.7, 20,
99, and 192pg/ml IL7, respectively). Finally to demonstrate that
product #1 could sustain #2, we mixed the cultures at a 1:4 ratio.
Over 3 weeks, CTL#1 progressively increased (14% to 87%), while
the frequency of CTL#2 progressively declined over the same period
(63% to 5%).71
HIGH-YIELD OF CD341 CELLS WITH BORTEZOMIB-BASED MOBILIZA-
TION REGIMEN IS ASSOCIATED WITH SPECIFIC GENOMIC EXPRESSION
PATTERNS, DECREASE IN SDF-1 PLASMA LEVELS AND UP-REGULATION
OF CXCR4 IN MULTIPLE MYELOMA (MM) PATIENTS
Ward, M.M.1, Mark, T.1, Manco, M.1, Stern, J.1, O’Loughlin, J.1,
Shore, T.B.1, Pearse, R.N.1, Jayabalan, D.1, Skerrett, D.2, Chen-
King, S.2, Lane, M.E.1, Niesvizky, R.1 1Weill Cornell Medical College,
New York, NY; 2New York, NY
Typical stem cell mobilization regimens in MM include G-CSF
alone or in combination with plerixafor or high-dose cyclophospha-
mide (CTX). Given the known in vitro/in vivo synergy between borte-
zomib (VELCADE, Vel) and alkylating agents, we investigated the
potential for concurrent cytoreduction by adding Vel to the mobiliza-
tion regimen. Eligible patients (pts) had symptomatic, Durie-Salmon
stage II/III MM. All pts received six 21-day cycles of Vel/dexametha-
sone6 liposomal doxorubicin. Cycle 7 only, mobilization (Vel-mob)
comprised Vel 1.3 mg/m2 on days 1, 4, 8, and 11, CTX 3 g/m2 on
day 8, and Filgrastim 10 ug/kg (rhG-CSF) for 10 days from day 9. At
data cut-off, 25pts havebeenmobilized. In comparison topts receiving
just G-CSF alone, there was a significant increase in the median
CD341 collection (22.6106/kgvs10.6106/kg). Inaddition, thenum-
ber of CD341 cells/kg collected far exceeded the study goal of
10X106cells/kg which is typical of using CTX and/or GCSF alone inStem Cells
fused (X106/kg)
Viability
(%)
Day of neutr.
engraftment
Day of plt.
engraftment
5.78 85 14 20
13.22 80 11 13
9.87 60 13 22
9.03 90 10 15
5.44 97 11 21
9.24 94 10 16
17.30 91 10 17
6.32 80 13 24
4.25, 2.74 80, 94 11 18
9.05 93 16 21
no transplant no transplant
12.83 85 11 11
7.38 93 11 11
10.02 92 12 14
12.72 87 13 11
5.31 93 11 13
6.66 92 12 13
9.2 95 11 20
7.40 92 10 11
11.06 98 10 21
no transplant no transplant
3.47 90 16 16
3.96 94 12 12
7.92 93 11 14
5.63 97 10 14
8.48 92 11 15
